All In Biotech

Drug Trial Radar · NCT06065540

A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,734 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,734

Actual

Start

Sep 27, 2023

Primary completion

Nov 19, 2025

Study completion Jan 6, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Oct 4, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine together with the current diabetes medicine (metformin with or without an SGLT2 inhibitor).

Conditions

  • Type 2 Diabetes Mellitus

Interventions

  • CagrilintideDrug

    Participants will receive once-weekly s.c injection of cagrilintide at escalating doses every week until maintenance dose 1 and dose 2 of cagrilintide is reached.

  • SemaglutideDrug

    Participants will receive once-weekly s.c injection of semaglutide at escalating doses every week until maintenance dose 1 and dose 2 of semaglutide is reached.

  • Placebo cagrilintideDrug

    Participants will receive placebo matched to cagrilintide subcutaneously.

  • Placebo semaglutideDrug

    Participants will receive placebo matched to semaglutide subcutaneously.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. CagriSema (dose 1) versus semaglutide (dose 1): Change in glycated haemoglobin (HbA1c)Time frame: From baseline (week 0) to end of treatment (week 68)

Locations

405 sites in 32 countries. Site status is shown where the registry gives one.

  • Synexus Clin Res-Birmingham

    Birmingham, Alabama

  • Univ of Alabama_Birmingham

    Birmingham, Alabama

  • Cahaba Research

    Pelham, Alabama

  • Velocity Clinical Research-Phoenix

    Phoenix, Arizona

  • Synexus Rsch /Cnt Phnx Med C

    Phoenix, Arizona

  • Arkansas Clinical Research

    Little Rock, Arkansas

  • Velocity Clinical Res-Banning

    Banning, California

  • Velocity Clin Res-Chula Vista

    Chula Vista, California

  • John Muir Physicians Network

    Concord, California

  • Headlands Research California, LLC

    Escondido, California

  • Velocity Clin Res Gardena

    Gardena, California

  • Velocity Clin Res San Diego

    La Mesa, California

  • Loma Linda Univ Hlth Cr Endo

    Loma Linda, California

  • Facey Medical Foundation

    Mission Hills, California

  • Desert Oasis Hlthcr Med Group

    Palm Springs, California

  • Velocity Clin Res- San Bern

    San Bernardino, California

  • Linda Vista Health Care Ctr

    San Diego, California

  • Velocity Clin Res Santa Ana

    Santa Ana, California

  • Premier Medical Center, Inc.

    Toluca Lake, California

  • Velocity Clin Res - Panorama

    Van Nuys, California

  • Optumcare Clinical Trials,LLC-Golden

    Colorado Springs, Colorado

  • Northeast Research Institute

    Jacksonville, Florida

  • Clinical Trial Services Corp

    Miami, Florida

  • Bioclinical Research Alliance

    Miami, Florida

  • New Horizon Research Center

    Miami, Florida

  • South Broward Research LLC

    Miramar, Florida

  • West Orange Endocrinology

    Ocoee, Florida

  • Optimal Research Sites

    Orange City, Florida

  • Advent Health-Res Inst

    Orlando, Florida

  • AdventHealth Diab Inst

    Orlando, Florida

  • Synexus Clin Res - Orlando

    Orlando, Florida

  • Oviedo Medical Research, LLC

    Oviedo, Florida

  • Hope Clin Res & Wellness

    Conyers, Georgia

  • East Coast Institute for Res

    Macon, Georgia

  • Urban Family Practice Assoc

    Marietta, Georgia

  • Endocrine Research Solutions, Inc.

    Roswell, Georgia

  • Endocrine Research Solutions

    Roswell, Georgia

  • Pacific Diabetes & Endo Ctr

    Honolulu, Hawaii

  • St. Luke's Health System

    Boise, Idaho

  • Solaris Clinical Research

    Meridian, Idaho

Showing 40 of 405 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.